In Depth 27 Jun 2023 The promise of immunotherapy for autoimmune diseases Our immune system serves as the body’s chief line of defense against harmful invaders. But what happens when this mighty defense mechanism turns on its own host, launching an assault on healthy cells and tissues? For the millions of people battling autoimmune diseases, this can severely affect their lives. However, advances in immunotherapy have revolutionized […] June 27, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 9 Jun 2023 Enhancing canine wellness: The promise of immunotherapy for dogs Given that dogs are widely regarded as ‘man’s best friend’, it makes sense that we are constantly striving to find ways to improve canine health and extend their lives. One method that has been – and is still being – explored is the use of immunotherapy, which uses a dog’s own immune system to fight […] June 9, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 11 May 2023 Battling food allergies: emerging immunotherapies While for most individuals, picking a restaurant to dine at could simply be based on what they might be craving at the moment, for about one to five per cent of the world’s population, this is a well-thought-out decision that involves ensuring there wouldn’t be any cross-contamination in the food which is bound to trigger […] May 11, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 May 2023 5 cancers that immunotherapy can cure Cancer immunotherapy dates back to 1891, when William Coley became the first person to try and harness the immune system to treat cancer. Since then, immunotherapy has become the mainstay of cancer treatment and is being used in the fight against many different types of cancer. When the first immune checkpoint inhibitor – which works […] May 9, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 3 May 2023 Immunotherapy in the fight against solid tumors Ever since William Coley first attempted to harness the immune system in 1891 to treat bone cancer, immunotherapy has been explored in the treatment of various different cancers – both solid and liquid – and has revolutionized and rejuvenated the field of oncology. However, despite certain immunotherapy treatments having shown very promising results, such as […] May 3, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 24 Apr 2023 RNA-based nanodrugs cause cancer cells to collapse – 80% survival rate for ovarian cancer in lab models Researchers from Tel Aviv University in Israel have revealed details of a new approach to the treatment of ovarian cancer using RNA-based nanodrugs – demonstrating an 80% survival rate in lab models.In a study at Tel Aviv University, the protein CKAP5 (cytoskeleton-associated protein) was used for the first time as a therapeutic target for RNA-based […] April 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Apr 2023 Researchers explain how some lung tumors avoid immunotherapy The oncogenic activation of MYC, a critical gene in cancer progression, has the potential to identify lung cancer patients who may respond poorly to immunotherapy. This is the main conclusion of a study recently published by a team of researchers led by Montse Sanchez-Cespedes, principal investigator of the Cancer Genetics group at the Josep Carreras […] April 14, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Vaccitech announces positive topline data for chronic hepatitis study Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […] March 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Mar 2023 10 immunotherapy companies making waves in 2023 Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses. Along with these technological advancements, […] March 15, 2023 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 How the microbiome can predict cancer immunotherapy success A new study shows antibiotic treatment prior to CAR-T cell therapy is connected to unfavorable treatment outcomes. An international team headed by Eran Elinav of the Cancer & Microbiome Division of the German Cancer Research Center (DKFZ), and led by Christoph Stein-Thoeringer, professor of Clinical Infectiology and Translational Microbiome Research at the Medical Faculty of […] March 14, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2023 AELIX announces ‘important step towards HIV eradication’ AELIX Therapeutics S.L., a clinical-stage biotechnology company specializing in the discovery and development of immunotherapies for HIV infection, has announced positive topline results from its AELIX-003 trial. The study evaluated the safety, tolerability, immunogenicity and efficacy of AELIX Therapeutics’ HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod […] February 24, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Cytovation melanoma study under way Cytovation ASA, a Norwegian clinical stage immune-oncology company focused on the development of CyPep-1, its first-in-class targeted tumor membrane immunotherapy, announces that the first patient has been dosed in its phase 2a study. The trial is investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors (CPIs). The study is an expansion arm […] February 16, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email